Immune Checkpoint Inhibitors - The Need for Innovation

N Engl J Med. 2023 Apr 20;388(16):1529-1532. doi: 10.1056/NEJMsb2300232.

Authors

P Connor Johnson¹, Justin F Gainor¹, Ryan J Sullivan¹, Dan L Longo¹, Bruce Chabner¹

Affiliation

¹ From the Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital (P.C.J., J.F.G., R.J.S., B.C.), and Harvard Medical School (P.C.J., J.F.G., R.J.S., B.C.) - both in Boston.

PMID: 37075146
DOI: 10.1056/NEJMsb2300232

No abstract available

MeSH terms

Antineoplastic Agents, Immunological* / adverse effects
Antineoplastic Agents, Immunological* / therapeutic use
Humans
Immune Checkpoint Inhibitors* / adverse effects
Immune Checkpoint Inhibitors* / therapeutic use
Immunotherapy
Inventions

Substances

Antineoplastic Agents, Immunological
Immune Checkpoint Inhibitors